Transparency, trust and the public interest
This article was originally published in SRA
How much transparency is needed for regulatory systems to function in the best interests of all concerned? The question arose recently in the context of the French (over-)reaction to the Mediator affair1.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.